Status:
UNKNOWN
Oral Isotretinoin in Melasma a Randomized Controlled Trial
Lead Sponsor:
Zagazig University
Conditions:
Melasma
Eligibility:
All Genders
18-50 years
Phase:
PHASE1
Brief Summary
Melasma is a common refractory acquired hyperpigmentation of the skin having a serious impact on patients' quality of life. Melasma is challenging to treat. Treatment is often a multimodality approach...
Detailed Description
Melasma has a significant impact on the quality of life and self-esteem of those affected. Darker skin photo types e.g. Egyptians have excess potential to develop melasma. Melasma is a chronic and ch...
Eligibility Criteria
Inclusion
- Age between 18 and 50 years
- Patients complaining of melasma.
- Patients with all types of melasma (epidermal, dermal and mixed)
- Sexually active women who is willing to follow at least 2 types of contraceptive methods during study period
- Patients with skin type I-V
Exclusion
- Pregnant or nursing women.
- Women on any concurrent therapy for melasma.
- Patients that are using any therapy for melasma for the last 45 days.
- Patient with abnormal liver function test or lipid profile.
- Patients with allergy or hypersensitivity to the assigned drugs.
- Women not willing to follow contraceptive methods at time of study.
- Patients on facial treatments or photosensitizing drugs within previous 6 months.
- Patients with back or joint pain.
- Patients with pre-existing or dormant dermatologic disease on the face that could interfere with the outcome of the study
Key Trial Info
Start Date :
March 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 31 2024
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06201624
Start Date
March 1 2023
End Date
May 31 2024
Last Update
January 11 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dermatology department, Zagazig University Hospitals, Faculty of Medicine, Zagazig University
Zagazig, Select Region, Egypt, 44511